Long‐term surveillance of SUDEP in drug‐resistant epilepsy patients treated with VNS therapy

@article{Ryvlin2018LongtermSO,
  title={Long‐term surveillance of SUDEP in drug‐resistant epilepsy patients treated with VNS therapy},
  author={Philippe Ryvlin and Elson L. So and Charles M. Gordon and Dale C. Hesdorffer and Michael R. Sperling and Orrin Devinsky and Mark T. Bunker and Bryan D. Olin and Daniel Friedman},
  journal={Epilepsia},
  year={2018},
  volume={59},
  pages={562 - 572}
}
Limited data are available regarding the evolution over time of the rate of sudden unexpected death in epilepsy patients (SUDEP) in drug‐resistant epilepsy. The objective is to analyze a database of 40 443 patients with epilepsy implanted with vagus nerve stimulation (VNS) therapy in the United States (from 1988 to 2012) and assess whether SUDEP rates decrease during the postimplantation follow‐up period. 

Norwegian population‐based study of long‐term effects, safety, and predictors of response of vagus nerve stimulation treatment in drug‐resistant epilepsy: The NORPulse study

This study was undertaken to evaluate the efficacy of vagus nerve stimulation (VNS) over time, and to determine which patient groups derive the most benefit.

Efficacy of VNS for Drug-Resistant Epilepsy in Structural Brain Lesions

There was no statistically significant difference between the two groups regarding RR, VNS settings, and other parameters, including anti-epileptic drug use and demographics data.

Long-term outcome in neurostimulation of epilepsy

The SANTÉ study at 10 years of follow‐up: Effectiveness, safety, and sudden unexpected death in epilepsy

The efficacy and safety of deep brain anterior thalamus stimulation after 7 and 10 years are evaluated and the incidence of sudden unexpected death in epilepsy and overall mortality in adults in the Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy study is reported.

Neurostimulation in people with drug‐resistant epilepsy: Systematic review and meta‐analysis from the ILAE Surgical Therapies Commission

Summarize the current evidence on efficacy and tolerability of vagus nerve stimulation (VNS), responsive neurostimulation (RNS), and deep brain stimulation (DBS) through a systematic review and

Sudden Unexpected Death in Epilepsy (SUDEP): How Do We Prevent This Childhood Tragedy?

  • B. MudigoudarJ. Wheless
  • Medicine, Psychology
    The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG
  • 2022
strategy to help minimize seizure occurrence, even with an occasional missed dose of medication, is to use antiseizure medications with a long half-life or extended-release products. These would

Vagus nerve stimulation for drug-resistant epilepsy

The evidence supporting the use of VNS, its impact on seizure frequency and quality of life, and common adverse effects of this therapy are discussed and practical guidance for the approach to and the management of patients with VNS in situ is included.

Practical considerations in epilepsy neurostimulation

Clinical practice has evolved from those established in pivotal trials, Guidance is now available for clinicians who wish to expand their approach, and choice of neuromodulation technique may be tailored to individual patients based on their epilepsy characteristics, risk tolerance, and preferences.

Practice trends and the outcome of neuromodulation therapies in epilepsy: A single‐center study

Epilepsy neuromodulation clinic can serve as an optimal solution for patients as well as providers due to rapid access, better continuity of care, higher recruitment for research studies, and training health professionals.
...

References

SHOWING 1-10 OF 31 REFERENCES

Mortality and SUDEP in epilepsy patients treated with vagus nerve stimulation

The aim was to calculate standardized mortality ratios (SMRs), identify epilepsy‐related deaths, and estimate sudden unexpected death in epilepsy (SUDEP) rates in patients treated with VNS for epilepsy.

Epilepsy, Vagal Nerve Stimulation by the NCP System, All‐Cause Mortality, and Sudden, Unexpected, Unexplained Death

The 2‐year extension of the study of mortality and sudden, unexpected, unexplained death in epilepsy (SUDEP) in the cohort of patients receiving vagal nerve stimulation by the NCP System for the treatment of epilepsy is extended.

Sudden unexpected death in epilepsy: Assessing the public health burden

This systematic review seeks to summarize the incidence of sudden unexpected death in epilepsy and its age distribution, as well as the years of potential life lost and cumulative risks of SUDEP for persons with epilepsy.

Vagus nerve stimulation for medication-resistant generalized epilepsy

VNS is an effective treatment for medication-resistant generalized epilepsy even in patients as young as 4 years, and patients with higher baseline seizure rates and later ages at epilepsy onset had the best responses to VNS.

Vagus nerve stimulation for medication-resistant generalized epilepsy. E04 VNS Study Group.

VNS is an effective treatment for medication-resistant generalized epilepsy even in patients as young as 4 years, and patients with higher baseline seizure rates and later ages at epilepsy onset had the best responses to VNS.

Prevention of sudden unexpected death in epilepsy: A realistic goal?

Developing effective prevention ofudden unexpected death in epilepsy will depend on better understanding of the pathophysiology of SUDEP to define the most appropriate targets of intervention, and identification of risk factors for SUDEP that would allow for the design of feasible clinical trials to test targeted interventions in high‐risk populations.

Long-term mortality in childhood-onset epilepsy.

BACKGROUND There are few studies on long-term mortality in prospectively followed, well-characterized cohorts of children with epilepsy. We report on long-term mortality in a Finnish cohort of

Sudden Unexpected Death in Epilepsy

  • M. NeiRyan Hays
  • Psychology, Medicine
    Current neurology and neuroscience reports
  • 2010
Uncontrolled epilepsy, particularly with generalized tonic–clonic seizures, appears to be the most highly associated modifiable risk factor for SUDEP.